Karyopharm Therapeutics earnings date
Karyopharm Therapeutics (25K0) Q2 2026 Earnings Report
DE:25K0 Q2 2026 EPS Results
- Actual EPS
- -EUR 2.08
- Consensus EPS
- -EUR 1.23
- Beat/Miss
- Missed by -EUR 0.85
- One Year Ago EPS
- -EUR 3.87
DE:25K0 Q2 2026 Revenue Results
- Actual Revenue
- EUR 29.98M
- Expected Revenue
- EUR 28.87M
- Beat/Miss
- Beat by +EUR 1.11M
- YoY Revenue Growth
- -11.86%
Earnings Announcement Details
- Quarter
- Q2 2026
- Date
- 08/13/2026
- Time
- Before Open
- Conference Call
- Thursday, August 13, 2026
Karyopharm Therapeutics's next earnings date is estimated for February 10, 2027, based on past reporting schedules.
Q2 2026 Earnings Call Audio
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
The call conveyed materially positive clinical and regulatory progress—most notably compelling Phase III SENTRY data, constructive FDA interactions around SVR35 as a surrogate endpoint, an on-track sNDA submission, publication/presentation of results, and steady XPOVIO commercial performance—positioning the company for a potential accelerated approval and a sizeable myelofibrosis market opportunity. Offsetting these positives are significant near-term financial risks: a missed endometrial cancer Phase III endpoint that reduced pipeline diversification, a widened reported net loss driven by non-cash financing impacts, limited cash runway (liquidity into September 2026) and an upcoming $15.8M loan payment that could trigger a covenant default without new financing or waivers. Regulatory timing uncertainty (need for long-term OS confirmatory data) and transitional expense pressures add further near-term risk. Overall, the call balanced strong clinical momentum and commercial readiness against pronounced short-term financial and execution risks.
Management reaffirmed 2026 guidance of $130–$150M total revenue (with U.S. XPOVIO net product revenue of $115–$130M and near‑term license/royalty revenue) and forecast combined R&D + SG&A of $230–$245M (excluding certain one‑time EC‑042 or financing costs); Q2 results showed $33.4M total revenue ($30.8M U.S. XPOVIO), a 26.6% gross‑to‑net rate, R&D $29M, SG&A $25.9M, and a net loss of $67M (vs. $37.3M LY) with an ~8% reduction in loss from operations. They ended the quarter with $65.4M in cash/cash equivalents/restricted cash/investments and expect existing liquidity to fund operations into September 2026 absent additional financing (a $15.8M term‑loan principal payment is due Sept 10, 2026 and could drop liquidity below a $10M covenant); the company is pursuing financing and strategic alternatives. Operationally, they remain on track to submit the sNDA in August using week‑24 SVR35 as the accelerated‑approval basis, expect SENTRY‑2 60 mg top‑line data in H2 2026, and indicated potential FDA filing acceptance/priority review and a possible approval/launch as early as Q1 2027, with U.S. peak revenue potential of ~ $1B (addressable market roughly 20,000 prevalent and ~4,000 new frontline patients/year).
- Planned sNDA Submission on TrackCompany remains on track to submit a supplemental New Drug Application (sNDA) for selinexor plus ruxolitinib in myelofibrosis in August 2026; constructive FDA interactions and written feedback indicating SVR35 may qualify as a 'reasonably likely' surrogate endpoint for overall survival.
- Strong Phase III SENTRY Data (SVR35 & OS)SENTRY Phase III demonstrated statistically significant, rapid, deep, and sustained spleen volume reduction (SVR35) with the combination vs ruxolitinib alone (nearly double spleen response rate at week 24); overall survival hazard ratio reported at 0.43 (suggesting a ~57% reduction in risk), with SVR35 at week 24 predicting OS.
- Subgroup Efficacy and Biological SignalsEfficacy observed across pre-specified subgroups; notable finding that with average ruxolitinib doses <15 mg/day, SVR35 with the combination reached as high as 50% versus 0% with ruxolitinib alone in that subgroup. Variant allele frequency (VAF) reductions were observed as early as week 24 and correlated with higher likelihood of achieving SVR35, supporting potential disease modification.
- Scientific Recognition and DisseminationSENTRY results were presented at major meetings (ASCO, EHA) and published in the Journal of Clinical Oncology, generating strong interest across the hematology community and ongoing scientific engagement ahead of potential approval.
- Commercial Foundation and Market OpportunityExisting hematology commercial platform (XPOVIO experience, KaryForward patient support, coverage in community and academic settings) positions the company for a rapid launch; company estimates up to approximately $1 billion peak annual U.S. revenue opportunity in myelofibrosis (approx. 20,000 prevalent patients, ~4,000 new frontline patients/year).
- Stable XPOVIO Revenue and Reaffirmed GuidanceQ2 U.S. XPOVIO net product revenue was $30.8 million vs $29.7 million in Q2 2025 (increase of ~3.7% YoY). Company reaffirmed full-year 2026 guidance: total revenue $130M–$150M and U.S. XPOVIO net product revenue $115M–$130M.
- Expense Discipline and Improved Underlying OperationsR&D expense decreased 12% YoY to $29.0M and SG&A decreased 9% YoY to $25.9M, reflecting prioritization of high-value programs. Underlying operating performance improved with an ~8% reduction in loss from operations (excluding non-cash financing mark-to-market impacts).
DE:25K0 Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 10, 2027 | 2026 (Q4) | ―- | -5.12 | ― | ― |
| Oct 29, 2026 | 2026 (Q3) | -0.30- | -3.43 | ― | |
| Aug 13, 2026 | 2026 (Q2) | -1.23-2.08 | -3.87 | 46.30% (+1.79) | |
| May 14, 2026 | 2026 (Q1) | -1.27-1.11 | -2.48 | 55.23% (+1.37) | |
| Feb 12, 2026 | 2025 (Q4) | -1.79-5.12 | -3.23 | -58.61% (-1.89) | |
| Nov 03, 2025 | 2025 (Q3) | -3.11-3.43 | -3.5 | 2.05% (+0.07) | |
| Aug 11, 2025 | 2025 (Q2) | -3.66-3.87 | -2.69 | -44.00% (-1.18) | |
| May 12, 2025 | 2025 (Q1) | -3.96-2.48 | -4.3 | 42.29% (+1.82) | |
| Feb 19, 2025 | 2024 (Q4) | -3.52-3.23 | -4.84 | 33.33% (+1.61) | |
| Nov 05, 2024 | 2024 (Q3) | -3.54-3.50 | -4.04 | 13.33% (+0.54) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.


